TrialLancet (London, England)2021

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Yelena Y Janjigian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.